

Harlan F Weisman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11296608/harlan-f-weisman-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

1,716
citations

12
h-index

18
g-index

18
ext. papers

1,824
ext. citations

6.8
avg, IF

3.03
L-index

#	Paper	IF	Citations
18	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 2059-65	15.1	115
17	ReoPro Clinical Development: A Case Study 2001 , 365-380		
16	The Evolution of ReoPro [®] Clinical Development 2000 , 323-346		1
15	Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. <i>American Heart Journal</i> , 2000 , 139, 696-703	4.9	39
14	Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. <i>Circulation</i> , 1999 , 99, 1951-8	16.7	127
13	Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist 1999 , 35-71		1
12	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies. <i>American Heart Journal</i> , 1999 , 137, S129-32	4.9	1
11	Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. <i>Circulation</i> , 1998 , 97, 1680-8	16.7	254
10	Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab; ReoPro) for the Prevention of Acute Ischemic Syndromes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1997 , 3, 256-266	3.3	6
9	Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. <i>Journal of the American College of Cardiology</i> , 1997 , 30, 149-56	15.1	179
8	Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. <i>American Journal of Cardiology</i> , 1997 , 79, 286-91	3	120
7	Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. <i>American Journal of Cardiology</i> , 1996 , 77, 1045-51	3	183
6	The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. <i>Molecular Immunology</i> , 1995 , 32, 1271-81	4.3	94
5	Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. <i>Journal of the American College of Cardiology</i> , 1995 , 26, 1665-71	15.1	146
4	Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. <i>American Journal of Cardiology</i> , 1995 , 75, 559-62	3	140
3	Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. <i>Circulation</i> , 1995 , 91, 2882-90	16.7	189
2	Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. <i>Annals of the New York Academy of Sciences</i> , 1991 , 614, 193-213	6.5	121

- 1 ReoPro Clinical Development: A Case Study 365-380